Navigation Links
Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
Date:12/5/2007

EMERYVILLE, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") presented interim results for XERECEPT(R) at the Annual Meeting for the Society of Neuro-Oncology.

Paul Freiman, President and Chief Executive Officer of NTI, stated, "We are pleased with our continuing involvement in the development of XERECEPT and the prospects for this drug, which is so urgently needed."

On December 4, 2007, Celtic Pharma, which acquired the rights and assets related to XERECEPT from NTI in November 2005, issued the following press release:

"New York, London and Bermuda, December 4, 2007 - Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today reported interim study results for XERECEPT(R) (human corticotropin-releasing factor (hCRF)), which were presented at the 12th Annual Meeting of the Society for Neuro-Oncology ("SNO"), and provided an update on the XERECEPT(R) clinical development program.

"In a poster presentation at the SNO annual meeting, which took place in Dallas, Texas on November 15-18, 2007, Celtic Pharma disclosed interim results of an on-going, open-label extension trial, which is evaluating the long-term safety and efficacy of XERECEPT(R) as a new potential treatment for Peritumoral Brain Edema ("PBE"), or tumor-related brain swelling. The data presented at SNO demonstrated that 20 of the first 32 patients enrolled received XERECEPT(R) daily for at least 20 weeks. XERECEPT(R) was well- tolerated. Nine of the 20 patients discontinued dexamethasone altogether, and steroid side effects were resolved or improved in the majority of patients who received a reduced dexamet
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
(Date:8/28/2015)... FARUM, Denmark and ATLANTA ... July 31, 2015 the US Food and Drug Administration (FDA) ... Major Depressive Disorder in adult patients who have failed to ... episode. TMS is a non-invasive technique for stimulating neural tissue ... from Major Depressive Disorder. The procedure has been proven safe ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... wound center management, Decatur County Memorial Hospital recently transitioned management companies to partner ... Wound Center Management for their outpatient wound center. , Transitioning wound care ...
(Date:8/28/2015)... ... 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn ... applying for, they are unable to pass the initial drug test and therefore unable ... in order to be able to hire long-term, skilled talent. (1) Will Wesch, Director ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing ... their subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart ... They believe that together, a difference can be made. Walkers can participate in the ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in ... Foundation has added yet another accolade to its cadre of widespread support—an official letter ... “With the help of the medical community and the University of Illinois at Chicago’s ...
(Date:8/28/2015)... ... , ... Saint Petersburg, FL —Pocket Protein™, a protein beverage ... gluten, lactose or caffeine in a convenient 2 oz. pouch that never needs ... Awards. , Five consumer packaged goods (CPG) products were selected by the SupplySide ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... FRANCISCO A further analysis of a previously published ... study of children with mild persistent asthma reports the ... children with differing demographic and clinical characteristics. ... in the TReating Children to Prevent Exacerbations of Asthma ...
... flu shot during pregnancy provides unanticipated benefits to the ... study examining the issue. Specifically, the study showed that ... significantly reduced risk of stillbirth, preterm birth and extremely ... Hospital Research Institute (OHRI), the CHEO Research Institute and ...
... , MONDAY, May 21 (HealthDay News) -- In a scenario ... found a way to perform nearly surgery-free gastric bypass procedures ... done with moveable magnets, is completed in less than a ... leaving behind any foreign material. Although pigs may not ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... used in some artificial sweeteners, may worsen Crohn,s disease by ... intestine, a new study suggests. However, researchers stressed that ... the lab, not in people, so it,s too soon to ...
... including a scientist from the Viral Immunology Center at ... herpesvirus infection of the eye is associated with neovascular ... in the elderly. The scientists found that human ... vascular endothelial growth factor, or VEGF, a signal protein ...
... to see that University of Cincinnati design students Alex Broerman ... design and prototype for a prescription-medicine pill bottle that better ... means of a simple and inexpensive innovation. In fact, ... their design a design intended to have universal appeal ...
Cached Medicine News:Health News:Baseline characteristics of children with mild persistent asthma predict response to ICS 2Health News:Flu shot during pregnancy shows unexpected benefits in large study 2Health News:Moveable Magnets Used to Forge Gastric Bypass in Pigs 2Health News:Moveable Magnets Used to Forge Gastric Bypass in Pigs 3Health News:Could Compound in Artificial Sweeteners Worsen Crohn's Disease? 2Health News:Could Compound in Artificial Sweeteners Worsen Crohn's Disease? 3Health News:Type of viral infection of eye associated with disease causing blindness in the elderly 2Health News:UC students design a better pill bottle for the blind and visually impaired 2Health News:UC students design a better pill bottle for the blind and visually impaired 3
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
... genuine BOOKWALTER™ Retractor System represents the ... design available. Its wide array of ... with a versatile system for multi-directional ... BOOKWALTER™ Kits are available for specific ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... Another breakthrough in real-time PCR analysis ... mutation analysis. ,The LightCycler 480 System ... and will meet the needs of ... in genomics research including array validation, ...
Medicine Products: